David Cullinane (Waterford, Sinn Fein)
Link to this: Individually | In context | Oireachtas source

616. To ask the Minister for Health if he will outline the role of the HSE corporate pharmaceutical unit and the National Centre for Pharmaeconomics; the number of whole-time equivalent staff assigned to the unit and centre respectively; and if he will make a statement on the matter. [35337/22]

Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

The National Centre for Pharmacoeconomics (NCPE) was established in 1998 and its remit is to advise the HSE and the Department of Health in relation to the cost-effectiveness of medicines, through the carrying out of health technology assessments (HTAs).

HSE decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds, on the advice of the NCPE. The NCPE conducts HTAs for the HSE and makes recommendations on reimbursement to assist HSE decisions. 

The NCPE's workload has increased significantly in recent years, from fewer than 10 assessments per year in 2007 to 98 assessments in 2021. In addition, the complexity of individual assessments has increased.

Following an independent review of the NCPE's work in 2017, an additional €750,000 was allocated by the Minister for Health in 2018 to support the working of the NCPE, increasing its staffing from 10.5 to 20.5 WTEs.

The HSE Corporate Pharmaceutical Unit (CPU) is the interface between the HSE and the Pharmaceutical Industry in relation to medicine pricing and reimbursement applications.

The HSE CPU is currently staffed by 12 WTEs.

David Cullinane (Waterford, Sinn Fein)
Link to this: Individually | In context | Oireachtas source

617. To ask the Minister for Health the role and composition of the HSE drugs group; and if he will make a statement on the matter. [35338/22]

Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

The HSE has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes, including the administration of the HSE Drugs Group, in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013; therefore, the matter has been referred to the HSE for reply to the Deputy.

David Cullinane (Waterford, Sinn Fein)
Link to this: Individually | In context | Oireachtas source

618. To ask the Minister for Health the composition of the HSE executive management team; and if he will make a statement on the matter. [35339/22]

Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

The HSE Senior Management Team is composed of 12 postholders.

They are:

1. The Chief Executive Officer

2. National Director Internal Audit

3. Head of Corporate Affairs

4. Chief Information Officer

5. Chief Clinical Officer

6. National Director of Communications

7. Chief Financial Officer

8. Chief Operations Officer

9. Chief Strategy Officer

10. National Director of Human Resources

11. National Lead Testing & Contract Tracing

12. Chief Technology Transformation Officer 

The structure in place at any time may be reconfigured in order to best respond to current challenges faced by the Health Service Executive in delivering better healthcare for the citizens of Ireland.